Fortis Institute of Blood Disorders, India is pioneering innovative treatments for challenging blood-related conditions

Muscat: Studies conducted by the Ministry of Health and Sultan Qaboos University (SQU)  on the prevalence of hereditary blood diseases in 2021, showed that 5.7 per cent of Oman’s population carries the gene for sickle cell anemia, and 2.61 per cent the gene for thalassemia (B).

A little more than one percent carry a gene for other sickle-cell diseases and nearly 10 per cent carry a gene from the genetic blood diseases genes in series (B), which are usually dangerous. More than 300 different genetic diseases in Oman have been identified.

Fortis Institute of Blood Disorders, Gurugram, India underscores the critical need for specialised care in blood disorders. In the rapidly evolving field of haemato-oncology, specialised expertise is crucial.

As the world witnesses a surge in blood cancer cases, Fortis is poised to bridge this gap and committed to providing accurate diagnoses, effective treatments, and integrated research, ensuring optimal patient outcomes.

Fortis Institute of Blood Disorders, stands as a beacon of advanced, targeted therapies, including innovative CAR-T cell therapy, combined with holistic care. We are proud to be at the forefront, providing world-class healthcare solutions. Our commitment to combining hematology expertise with the latest medical technology promises to significantly improve the lives of patients in India and beyond. So Far, more than 50 Patients from Oman have been treated at Fortis for blood related ailments. Fortis Institute of Blood Disorders, in Gurugram, India, has established itself as a leader in treatment of Blood associated ailments.

Fortis has a dedicated team of doctors comprising of Pediatric and Adult hematologists, genetic counselors, and support staff who work together to create personalised treatment plans.

These plans consider each patient’s unique needs and medical history, ensuring optimal care.

Treatment options may include Chemotherapies, CART Cell therapies and Bone Marrow Transplantations, a procedure Fortis has successfully performed on patients with Immunodeficiencies, Thalassemia, Sickle Cell Anemia, Leukemias and other blood and immune system related disorders.